ABBV-744
ABBV-744 is a BDII-selective BET bromodomain inhibitor targeting BRD2, BRD3, and BRD4. It is a research tool for investigating cancers, inflammatory diseases, and HIV/AIDS, with studies demonstrating its activity in both cellular and animal models.
Product Specifications
CAS Number
2138861-99-9
Product Name Alternative
ABBV 744, ABBV744, ABBV-744, Antitumor, BET bromodomain, Drug-like, CYP3A4, Oral, LNCaP, Inhibitor, inhibit, HIVProtease, HIV Protease, HIV, EpigeneticReaderDomain, Epigenetic Reader Domain, Human immunodeficiency virus, Selective, Potent
Field of Research
Epigenetics & Chromatin, Infectious Disease & Virology, Protein Biochemistry
Purity
97.03% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.07 mM) ; DMSO:230 mg/mL (467.91 mM)
Smiles
CCNC (=O) C1=CC2C (=CN (C) C (=O) C=2N1) C3C (=CC=C (C (C) (C) O) C=3) OC4=C (C) C=C (F) C=C4C
Molecular Formula
C28H30N3O4F
Molecular Weight
491.5527
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
